Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload

Acta Haematologica

Volumn 120, Issue 2, 2008, Pages 123-128

  Otto Duessel, Maya ^a   Brewer, Casey ^a   Gonzalez, Ignacio ^a   Nick, Hanspeter ^b   Wood, John C ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Deferasirox; Deferoxamine; Iron overload

Indexed keywords

DEFERASIROX; DEFEROXAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHELATION THERAPY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GERBIL; HEART MUSCLE NECROSIS; IRON OVERLOAD; MONOTHERAPY; MYOCARDITIS; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL;

ANIMALS; BENZOIC ACIDS; DEFEROXAMINE; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; DRUG TOXICITY; GERBILLINAE; HEART; IRON OVERLOAD; LIVER; ORGAN SIZE; TREATMENT OUTCOME; TRIAZOLES;

EID: 56149116825     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000174757     Document Type: Article

References (26)

1. Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, Sabato V, Melevendi C, Cappellini MD, Verlato G: Survival and disease complications in thalassemia major. Ann NY Acad Sci 1998;850:227-231.
2. Lerner N, Blei F, Bierman F, Johnson L, Piomelli S: Chelation therapy and cardiac status in older patients with thalassemia major. Am J Pediatr Hematol Oncol 1990;12:56-60.
3. Aldouri MA, Wonke B, Hoffbrand AV, Flynn DM, Ward SE, Agnew JE, Hilson AJ: High incidence of cardiomyopathy in beta-thalassaemia patients receiving regular transfusion and iron chelation: reversal by intensified chelation. Acta Haematol 1990;84:113-117.
4. Modell B, Khan M, Darlison M: Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000;355:2051-2052.
5. Schrier S, Angelucci E: New strategies in the treatment of the thalassemias. Annu Rev Med 2005;56:157-171.
6. Daar S, Taher A, Pathare A: Plasma LPI in beta-thalassemia patients before and after treatment with deferasirox (Exjade®, ICL670). Blood 2005;106:758a.
7. Glickstein H, El RB, Shvartsman M, Cabantchik ZI: Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 2005;106:3242-3250.
8. Anderson LJ, Westwood MA, Prescott E, Walker JM, Pennell DJ, Wonke B: Development of thalassaemic iron overload cardiomyopathy despite low liver iron levels and meticulous compliance to desferrioxamine. Acta Haematol 2006;115:106-108.
9. Otto-Duessel M, Aguilar M, Moats R, Wood JC: Antioxidant-mediated effects in a gerbil model of iron overload. Acta Haematol 2007;118:193-199.
10. Cohen AR, Glimm E, Porter JB: Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood 2008;111:583-587.
11. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R, Krebs-Brown AJ, Anderson JR, Alberti D, Sizer KC, Nathan DG: Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003;361:1597-1602.
12. Porter J, Galanello R, Saglio G, Neufeld EJ, Vichinsky E, Cappellini MD, Olivieri N, Piga A, Cunningham MJ, Soulières D, Gattermann N, Tchernia G, Maertens J, Giardina P, Kwiatkowski J, Quarta G, Jeng M, Forni GL, Stadler M, Cario H, Debusscher L, Della Porta M, Cazzola M, Greenberg P, Alimena G, Rabault B, Gathmann I, Ford JM, Alberti D, Rose C: Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-year prospective study. Eur J Haematol 2007;80:168-176.
13. Cappellini MD, Bejaoui M, Perrotta S, Agaoglu L, Kattamis A, Giardina PJ, Janka-Schaub G, Opitz H, Ressyare-Djaffer C, Alberti D: A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107:3455-3462.
14. Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C: Exploring the 'iron shuttle' hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med 2001;138:130-138.
15. Hershko C, Abrahamov A, Konijn AM, Breuer W, Cabantchik IZ, Pootrakul P, Link G: Objectives and methods of iron chelation therapy. Bioinorg Chem Appl 2003;151-168.
16. Glickstein H, El RB, Link G, Breuer W, Konijn AM, Hershko C, Nick H, Cabantchik ZI: Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 2006;108:3195-3203.
17. Yang T, Brittenham GM, Dong WQ, Levy MN, Obejero-Paz CA, Kuryshev YA, Brown AM: Deferoxamine prevents cardiac hypertrophy and failure in the gerbil model of iron-induced cardiomyopathy. J Lab Clin Med 2003;142:332-340.
18. Wood J, Otto-Duessel M, Aguilar M, Nick H, Moats R: Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Transl Res 2006;148:272-280.
19. Wood JC, Otto-Duessel M, Aguilar M, Nick H, Nelson MD, Coates TD, Pollack H, Moats R: Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation 2005;112:535-543.
20. Wood JC, Otto-Duessel M, Aguilar M, Nick H, Coates TD, Moats R: Dose response of deferoxamine, deferiprone, and ICL670 chelation therapy in a gerbil model of iron overload. Blood 2004;104:985a.
21. Oates PS, Jeffrey GP, Basclain KA, Thomas C, Morgan EH: Iron excretion in iron-overloaded rats following the change from an iron-loaded to an iron-deficient diet. J Gastroenterol Hepatol 2000;15:665-674.
22. Hershko C, Konijn AM, Nick HP, Breuer W, Cabantchik ZI, Link G: ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood 2001;97:1115-1122.
23. Otto-Duessel M, Aguilar M, Nick H, Moats R, Wood J: Comparison of BID versus QD deferasirox dosing in a gerbil model of iron cardiomyopathy. Exp Hematol 2007;35:1069-1073.
24. Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, Porter JB, Walker JM, Pennell DJ: Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004;127:348-355.
25. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood M, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ: A randomized, placebo-controlled, doubleblind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007;115:1876-1884.
26. Cable EE, Connor JR, Isom HC: Accumulation of iron by primary rat hepatocytes in long-term culture. Am J Pathol 1998;152:781-792.